Afya Limited

Aktienanalyse zu Afya Limited (AFYA)

$14.530

+0.010 (+0.07%)Zum Schluss

Loading chart…
Hoch
14.670
Eröffnung
14.520
Volumengewichteter Durchschnittskurs
14.54
Volumen
194.16K
Marktkap.
1.53B
Tief
14.420
Umsatz
2.82M
EV/EBITDA, TTM
2.02

Afya Ltd is a Brazil-based company engaged in the education sector. The Company is mainly focused on operating medical schools, offering health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition and biomedicine. In addition, the Firm provides degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering and pedagogy. The Company's methodological approach combines integrated content, interactive learning, and an adaptive experience for learners. Through its educational content and technology-enabled activities, the Company focuses on personalized learning that mirrors one-on-one tutoring. The Company's undergraduate and graduate campuses are spread across Brazil, as well as its digital medical platform.

ir.afya.com.br

KI-Analyse of Afya Limited (AFYA)

Kaufen

Afya Ltd is a good buy right now due to its strong financial performance, reflected in a gross margin of 61.59% and a forward P/E ratio of 7.86. The recent revenue growth of 7% year-over-year and the significant analyst upgrades provide a solid foundation for potential price appreciation. However, the risk is highlighted by the insider selling activity, which has increased by 1215.03% over the last month, indicating potential concerns among insiders.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Afya Limited (AFYA) beträgt 7.86, verglichen mit dem 5-Jahres-Durchschnitt von 10.93.

Erwartetes KGV

Unterbewertet
5J-Durchschnitt P/E
10.93
Aktuelles P/E
7.86
Überbewertet
13.61
Unterbewertet
8.25

Erwartetes EV/EBITDA

Unterbewertet
5J-Durchschnitt EV/EBITDA
6.34
Aktuelles EV/EBITDA
2.02
Überbewertet
8.56
Unterbewertet
4.13

Erwartetes KUV

Stark unterbewertet
5J-Durchschnitt P/S
2.08
Aktuelles P/S
0.30
Überbewertet
2.95
Unterbewertet
1.20

Alphio-AI-Kursszenarien für AFYA

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%AFYA

$28.55

Szenariopreis

B

Basis

Basis · 50%AFYA

$24.23

Szenariopreis

B

Bärisch

Bärisch · 25%AFYA

$20.66

Szenariopreis

Whales, die AFYA halten

S

SoftBank Group Corp.

+ HältAFYA

-15.12%

3-Monats-Rendite

Event-Zeitleiste

2026-08-24 (ET)

10:00:00

Afya and Yduqs Discuss Potential Business Combination

2025-11-12 (ET)

18:14:48

Afya announces Q3 adjusted EBITDA of R$398.9M, a 14.6% increase year-over-year

2025-11-07 (ET)

08:54:49

Afya Reveals Expansion of Medical Seats at ITPAC Porto Nacional

News

AFYA FAQ – beantwortet von Alphio AI

Afya Ltd is a Brazil-based company engaged in the education sector. The Company is mainly focused on operating medical schools, offering health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition and biomedicine. In addition, the Firm provides degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering and pedagogy. The Company's methodological approach combines integrated content, interactive learning, and an adaptive experience for learners. Through its educational content and technology-enabled activities, the Company focuses on personalized learning that mirrors one-on-one tutoring. The Company's undergraduate and graduate campuses are spread across Brazil, as well as its digital medical platform. It operates in the Academic & Educational Services sector.

Afya Ltd is a good buy right now due to its strong financial performance, reflected in a gross margin of 61.59% and a forward P/E ratio of 7.86. The recent revenue growth of 7% year-over-year and the significant analyst upgrades provide a solid foundation for potential price appreciation. However, the risk is highlighted by the insider selling activity, which has increased by 1215.03% over the last month, indicating potential concerns among insiders.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln